Quest for a Cure

Thank you to all those who tuned in to our virtual Quest for a Cure Event!

If you did have a chance to join us live, you can still watch the event at the below link. We hope you’ll consider donating as well:


The Castleman Disease Collaborative Network (CDCN) invites you to the 7th annual Quest for a Cure Benefit! This year’s virtual benefit joined together our largest group of patients, loved ones, and community members to raise awareness and funds for life-saving Castleman disease research. We had an exciting program planned for the evening that included remarks from the
CDCN’s co-founder, Dr. David Fajgenbaum, physician-scientist at the University of Pennsylvania, and the author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action.

  • #FlexForACure Challenge:
    • Congratulations to Baby David Carter Fajgenbaum- this years #FlexForACure Challenge winner! (Check out his photo here.)

Sponsorships

There is still time to support our life-saving immunology research to discover cures for Castleman disease, COVID-19, and related diseases by donating here.

Royal Court Sponsor $50,000

  • Recognition on website and materials publicizing the event
  • Receive a Royal Court sponsor basket 

Crusader Sponsor $25,000

  • Recognition on website and materials publicizing the event
  • Receive a Crusader sponsor basket

Castleman Sponsor $10,000

  • Recognition on website and materials publicizing the event
  • Receive a Castleman sponsor basket

King Sponsor $5,000

  • Recognition on website and materials publicizing the event
  • Receive a King sponsor basket

Knight Sponsor $2,500

  • Recognition on website and materials publicizing the event

Bishop Sponsor $1,250

  • Recognition on website and materials publicizing the event

Noble Sponsor $500

  • Recognition on website and materials publicizing the event

 

 

 

 

We have included a few exciting developments below which we will highlight on November 11th:

1) Thanks to funding and support from our community, the CDCN recently discovered ANOTHER new treatment approach for Castleman disease and we have already begun trying it in patients without other options–with early success–including a case report published in The Lancet! Check out this link for more information. After 25 years without a single new treatment approach before the CDCN, this is the second new treatment approach that Dr. Fajgenbaum and the CDCN has discovered in the last 9 years. The first was sirolimus, which Dr. Fajgenbaum tested on himself and he described searching for in the national bestseller, Chasing My Cure: A Doctor’s Race to Turn Hope Into Action.   

2) In addition to discovering a new treatment, the CDCN has advanced over a dozen high-impact studies and published key papers including the first-ever diagnostic and treatment guidelines for unicentric Castleman disease, characterization of the most deadly subtype of Castleman disease, and taking the lead in defining cytokine storm through a paper in the New England Journal of Medicine.

3) We also continue to lead the biomedical community in drug repurposing — taking drugs approved for one disease and searching for additional diseases that they may be effective in. Through a partnership with the Chan Zuckerberg Initiative, we are mapping out the optimal paths to ensure that we are fully utilizing all of humankind’s drug discoveries for all diseases that they may be effective in.

4) The CDCN continues to push forward the CORONA (COvid19 Registry of Off-label & New Agents) Project, which we launched in March 2020 and is now the world’s largest effort to identify and track treatments for COVID-19. We have contributed to better understanding of COVID treatments, identifying promising treatments for large trials, and synthesizing evidence on effective approaches. 

About the CDCN

The CDCN’s innovative approach to transforming Castleman disease research over the last eight years has resulted in the first diagnostic criteria for Castleman disease, first treatment guidelines, first new drug target in 25 years, and the first clinical trial for patients with treatment-refractory Castleman disease. This work has been profiled on Good Morning America, New York Times, CNN, Philadelphia InquirerNPR Fresh Air, and the Lifetime TV NetworkThe CDCN has also partnered with the Chan Zuckerberg Initiative to expand the CDCN’s approach to research to advance cures for other rare diseases. 

More Information

  • Prefer to send a check by mail? Make out to “CDCN” (Castleman Disease Collaborative Network), notate ‘Quest for A Cure,’ and send to Castleman Disease Collaborative Network, PO Box 3614 Paso Robles, CA 93447
  • Questions? Email quest@castlemannetwork.org or call (610) 304-0696
  • CDCN is a 501 (c) (3) nonprofit organization. All donations are tax-deductible in accordance with IRS regulations.

 

 

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left